• Int. J. Infect. Dis. · Feb 2021

    Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.

    • A Balkhair, I Al-Zakwani, M Al Busaidi, A Al-Khirbash, S Al Mubaihsi, H BaTaher, J Al Aghbari, I Al Busaidi, M Al Kindi, S Baawain, A Al Alawi, A Al Lawati, B Al Rawahi, K Al-Baimani, K Al Zidi, N Elfatih, B Dawud, B John, F Rehman, F Yousif, G Al Khadouri, I Saber, J Lal, M Gargouri, M Al-Ward, N AbuDraz, S Al Ruqeishi, S Kumar, W Abdelmottaleb, Z Al-Naamani, Z Bin Nazar, and O Balkhair.
    • Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman. Electronic address: balkhair2020@gmail.com.
    • Int. J. Infect. Dis. 2021 Feb 1; 103: 288-296.

    ObjectiveThe aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.MethodsA prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were the need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who had received standard treatment and supportive care.ResultsA total of 69 patients were included: 45 treated with anakinra and 24 historical controls. A need for mechanical ventilation occurred in 14 (31%) of the anakinra-treated group and 18 (75%) of the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) of the anakinra-treated group and 11 (46%) of the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) of the anakinra-treated group compared with 6 (27%) of the historical cohort (p = 0.008). Patients who received anakinra showed a significant reduction in inflammatory biomarkers.ConclusionIn patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit.Trial Registration NumberISRCTN74727214.Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.